Skip to Main Content

The year is almost over! Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the fourth quarter:

Biogen has maintained a constant presence in STAT’s quarterly scorecards and this one is no different. Of course, all eyes are on Aduhelm and the thus-far poor U.S. commercial launch. What will CEO Michel Vounatsos say about the embattled Alzheimer’s treatment when the company reports third-quarter earnings? Will Biogen announce cost-cutting measures, including layoffs? And what will be Aduhelm’s fate in Europe, where regulators there are expected to render an approval decision in October or November? Looking beyond Alzheimer’s, Biogen is expected to have a readout on a drug called tofersen, which is being investigated in a Phase 3 clinical trial for patients with SOD1 ALS, a rapidly progressing form of the fatal neurodegenerative disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment